Related Experiment Video

Updated: Aug 22, 2026

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Progress in the field of GPIIb/IIIa antagonists

Julien Hanson1, Xavier de Leval, Jean-Louis David

  • 1Natural and Synthetic Drugs Research Centre, Department of Medicinal Chemistry, University of Liège, 1, av. de l'Hôpital, B36 Sart-Tilman, B-4000 Liège, Belgium.

Current Medicinal Chemistry. Cardiovascular and Hematological Agents
|August 24, 2004
PubMed

Insights

Platelet aggregation inhibitors, like glycoprotein IIb/IIIa antagonists, are crucial for cardiovascular disease treatment. This review details current and emerging drugs targeting this pathway.

Area of Science:

  • Cardiovascular Pharmacology
  • Thrombosis Research
  • Drug Development

Background:

  • Platelet aggregation is central to thrombotic cardiovascular diseases like myocardial infarction and stroke.
  • Inhibition of platelet aggregation is a key therapeutic strategy for preventing these conditions.
  • The glycoprotein IIb/IIIa receptor is a critical target for antiplatelet agents.

Purpose of the Study:

  • To review the chemical, pharmacological, and clinical profiles of existing and novel glycoprotein IIb/IIIa antagonists.
  • To discuss the development of oral agents for cardiovascular disease prevention and treatment.
  • To highlight the ongoing research in glycoprotein IIb/IIIa antagonism.

Main Methods:

  • Literature review of existing and preclinical/clinical stage glycoprotein IIb/IIIa antagonists.
  • Analysis of chemical structures, pharmacological mechanisms, and clinical trial outcomes.
  • Synthesis of information on marketed intravenous agents and investigational oral compounds.

Main Results:

  • Three intravenous glycoprotein IIb/IIIa antagonists (Abciximab, Eptifibatide, Tirofiban) are approved for specific cardiovascular interventions.
  • Early oral glycoprotein IIb/IIIa antagonists showed limited clinical success.
  • Numerous new orally active compounds are in development for cardiovascular indications.

Conclusions:

  • Glycoprotein IIb/IIIa antagonists remain a significant focus in cardiovascular drug development.
  • Despite past challenges, the pursuit of effective oral agents continues due to their therapeutic potential.
  • Further research into novel orally active compounds is essential for improving cardiovascular disease management.

More Related Videos

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...